Euglycemic Diabetic Ketoacidosis (EDKA): An easy to miss complication in Diabetic patients on Sodium Glucose Cotransporter 2(SGLT2) Inhibitors.


  • Dr. Balaji Venkatachalam Vijaya Medical and Educational Trust
  • Dr. Venkatesh N Vijaya Medical and Educational Trust


Diabetes Mellitus, SGLT-2 inhibitors, EDKA, DKA, Insulin


Euglycemic DKA is often a missed clinical entity which may increase the morbidity and mortality of inpatients. An apparently normal blood sugar levels often leads to diagnostic delay in EDKA.  Blood gas analysis and serum ketones estimation in the appropriate clinical setting should be done to clinch the diagnosis. Objective: To highlight the etio-pathogenesis of EDKA, risk factors, principles of management and therapeutic end points. Discussion: EDKA is being increasingly recognised in Type 2 Diabetes patients, with the introduction of SGLT2 inhibitors. Precipitating factors for EDKA include thin built-underweight patients on SGLT2 inhibitors, inadvertent continuation of SGLT2 inhibitors during sick days along with poor fluid intake etc. This euglycemic state is due to urinary excretion of glucose in the background of insulin deficiency. Once EDKA is established, SGLT2 inhibitor should be discontinued immediately and patient should be treated with standard DKA fluid management protocol. Fluid resuscitation should be continued till urine glycosuria disappears. Conclusion: Prompt and timely recognition of SGLT2 inhibitors induced EDKA and appropriate fluid resuscitation will avoid unnecessary complications and morbidity associated with the condition.


Bersten A & Handy J M (2018). OH’s Intensive Care Manual. Elsevier. Eighth edition. chapter 59;732-739.!/content/book/3-s2.0-B9780702072215000596

Nasa, P., Chaudhary, S., Shrivastava, P. K., & Singh, A. (2021). Euglycemic diabetic ketoacidosis: A missed diagnosis. World journal of diabetes, 12(5), 514–523.

Yu, X., Zhang, S., & Zhang, L. (2018). Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. International journal of endocrinology, 2018, 7074868.

Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017). Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes/metabolism research and reviews, 33(8), 10.1002/dmrr.2924.

Modi, A., Agrawal, A., & Morgan, F. (2017). Euglycemic Diabetic Ketoacidosis: A Review. Current diabetes reviews, 13(3), 315–321.

Chua, H. R., Schneider, A., & Bellomo, R. (2011). Bicarbonate in diabetic ketoacidosis - a systematic review. Annals of intensive care, 1(1), 23.

Lopaschuk, G. D., & Verma, S. (2020). Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC. Basic to translational science, 5(6), 632–644.

Lewis, S. R., Pritchard, M. W., Evans, D. J., Butler, A. R., Alderson, P., Smith, A. F., & Roberts, I. (2018). Colloids versus crystalloids for fluid resuscitation in critically ill people. The Cochrane database of systematic reviews, 8(8), CD000567.




How to Cite

Venkatachalam, B., & N, V. (2023). Euglycemic Diabetic Ketoacidosis (EDKA): An easy to miss complication in Diabetic patients on Sodium Glucose Cotransporter 2(SGLT2) Inhibitors. The Journal of Medicine and Science, 1(02), 17–22. Retrieved from



Review article